Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NQO2 | P16083 | 4/20 | 0.45 |
| ▸ | PARP1 | P09874 | 6/20 | 0.42 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.38 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2000196 | 0.85 | MAPT (0.44) | MAPTPARP1PSMD14MEN1KMT2A | |
| SCHEMBL28892424 | 0.79 | PARP1 (0.55) | PARP1PSMD14MEN1KMT2A | |
| SCHEMBL2000267 | 0.79 | PPARG (0.67) | PPARG | |
| SCHEMBL1999975 | 0.76 | ALOX15 (0.47) | MAPTNQO2KMT2APPARGNPBWR1 | |
| SCHEMBL1999265 | 0.76 | PPARG (0.69) | PPARG | |
| SCHEMBL343891 | 0.75 | PSMD14 (0.51) | PARP1PSMD14KMT2A | |
| SCHEMBL6420958 | 0.73 | PARP1 (0.68) | PARP1PSMD14KMT2A | |
| SCHEMBL633564 | 0.72 | PPARG (0.58) | PPARG | |
| SCHEMBL9125289 | 0.72 | PSMD14 (0.50) | MAPTPARP1PSMD14KMT2A | |
| SCHEMBL344980 | 0.71 | PSMD14 (0.43) | MAPTPARP1PSMD14KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1192137-B1 | COMPOUNDS FOR THE MODULATION OF PPAR-GAMMA ACTIVITY | AMGEN INC (US) | 2013-10-23 | — | — | EP | disclosed |
| US-7968567-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7960408-B2 | Quinolinyl and benzothiazolyl modulators | AMGEN INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100113522-A1 | COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY | AMGEN INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-7626033-B2 | Compounds for the modulation of PPARγ activity | AMGEN INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7601841-B2 | Quinolinyl and benzothiazolyl modulators | AMGEN INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090221635-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | AMGEN INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20060264481-A1 | Therapeutic modulation of PPARgamma activity | AMGEN INC. (US) | 2006-11-23 | — | — | US | disclosed |
| EP-1722789-A2 | THERAPEUTIC MODULATION OF PPAR (GAMMA) ACTIVITY | Amgen Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1296967-B1 | BENZOTHIAZOLYL PPAR-GAMMA MODULATORS | AMGEN INC (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20040176409-A1 | Quinolinyl and benzothiazolyl modulators | TULARIK INC | 2004-09-09 | — | — | US | disclosed |
| US-6770648-B2 | ANTIDIABETIC AGENTS | TULARIK INC. | 2004-08-03 | — | — | US | disclosed |
| US-20030171399-A1 | Quinolinyl and benzothiazolyl modulators | TULARIK INC. | 2003-09-11 | — | — | US | disclosed |
| US-20030139390-A1 | Compounds for the modulation of PPARgamma activity | TULARIK INC. | 2003-07-24 | — | — | US | disclosed |
| US-6583157-B2 | Peroxisome proliferator-activated receptors antagonists; antiinflammatory agents and treating metabolic disorders | TULARIK INC. | 2003-06-24 | — | — | US | disclosed |
| EP-1296967-A1 | QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS | Tularik Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20020169185-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | AMGEN INC. | 2002-11-14 | — | — | US | disclosed |
| EP-1192137-A1 | COMPOUNDS FOR THE MODULATION OF PPAR$g(g) ACTIVITY | Tularik Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2002000633-A1 | QUINOLINYL AND BENZOTHIAZOLYL PPAR-GAMMA MODULATORS | TULARIK INC. (US) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001000579-A1 | COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY | TULARIK INC. (US) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264481-A1 | Therapeutic modulation of PPARgamma activity | PPARG, PPARA, PPARD | MAPT 708/4885NQO2 2319/4885PARP1 1193/4885 |
| US-20030139390-A1 | Compounds for the modulation of PPARgamma activity | PPARG, PPARA, PPARD | MAPT 4694/4885NQO2 1347/4885PARP1 3362/4885 |
| US-20040176409-A1 | Quinolinyl and benzothiazolyl modulators | PPARA, PPARG, PPARD | MAPT 3145/4885NQO2 77/4885PARP1 2801/4885 |
| US-20100113522-A1 | COMPOUNDS FOR THE MODULATION OF PPARgamma ACTIVITY | PPARG, PPARA, PPARD | MAPT 4679/4885NQO2 1228/4885PARP1 3208/4885 |
| US-20030171399-A1 | Quinolinyl and benzothiazolyl modulators | PPARA, PPARG, PPARD | MAPT 3145/4885NQO2 77/4885PARP1 2801/4885 |
| US-20020169185-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | PPARA, PPARG, PPARD | MAPT 3145/4885NQO2 77/4885PARP1 2801/4885 |
| US-20090221635-A1 | QUINOLINYL AND BENZOTHIAZOLYL MODULATORS | PPARG, PPARA, PPARD | MAPT 3019/4885NQO2 71/4885PARP1 2558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.